Evidence map›Paper›PMID 39392163›Full record

ArticleJournal of the American Heart Association2024

Performance of a Protein Language Model for Variant Annotation in Cardiac Disease.

Aviram Hochstadt, Chirag Barbhaiya, Anthony Aizer, Scott Bernstein, Marina Cerrone, Leonid Garber, Douglas Holmes, Robert J Knotts, Alex Kushnir, Jacob Martin and 5 more

Abstract read
In one paragraph

Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Functional Evaluation ofbioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Aviram HochstadtNYU Langone Health and the NYU Grossman School of Medicine New York NY.ORCID 0000-0002-9404-3145
Chirag BarbhaiyaNYU Langone Health and the NYU Grossman School of Medicine New York NY.
Anthony AizerNYU Langone Health and the NYU Grossman School of Medicine New York NY.ORCID 0000-0001-6550-0178
Scott BernsteinNYU Langone Health and the NYU Grossman School of Medicine New York NY.
Marina CerroneNYU Langone Health and the NYU Grossman School of Medicine New York NY.ORCID 0000-0002-6122-9939
Leonid GarberNYU Langone Health and the NYU Grossman School of Medicine New York NY.
Douglas HolmesNYU Langone Health and the NYU Grossman School of Medicine New York NY.
Robert J KnottsNYU Langone Health and the NYU Grossman School of Medicine New York NY.
Alex KushnirNYU Langone Health and the NYU Grossman School of Medicine New York NY.ORCID 0000-0003-1644-643X
Jacob MartinNYU Langone Health and the NYU Grossman School of Medicine New York NY.ORCID 0000-0003-3515-132X
David ParkNYU Langone Health and the NYU Grossman School of Medicine New York NY.ORCID 0000-0001-5858-5353
Michael SpinelliNYU Langone Health and the NYU Grossman School of Medicine New York NY.
Felix YangNYU Langone Health and the NYU Grossman School of Medicine New York NY.ORCID 0000-0001-8751-6752
Larry A ChinitzNYU Langone Health and the NYU Grossman School of Medicine New York NY.
Lior JankelsonNYU Langone Health and the NYU Grossman School of Medicine New York NY.ORCID 0000-0003-2714-2212

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGenetic testing is a cornerstone in the assessment of many cardiac diseases. However, variants are frequently classified as variants of unknown significance, limiting the utility of testing. Recently, the DeepMind group (Google) developed AlphaMissense, a unique artificial intelligence-based model, based on language model principles, for the prediction of missense variant pathogenicity. We aimed to report on the performance of AlphaMissense, accessed by VarCardio, an open web-based variant annotation engine, in a real-world cardiovascular genetics center. METHODS AND

resultsAll genetic variants from an inherited arrhythmia program were examined using AlphaMissense via VarCard.io and compared with the ClinVar variant classification system, as well as another variant classification platform (Franklin by Genoox). The mutation reclassification rate and genotype-phenotype concordance were examined for all variants in the study. We included 266 patients with heritable cardiac diseases, harboring 339 missense variants. Of those, 230 (67.8%) were classified by ClinVar as either variants of unknown significance or nonclassified. Using VarCard.io, 198 variants of unknown significance (86.1%, 95% CI, 80.9-90.3) were reclassified to either likely pathogenic or likely benign. The reclassification rate was significantly higher for VarCard.io than for Franklin (86.1% versus 34.8%,

conclusionsAlphaMissense, accessed via VarCard.io, may be a highly efficient tool for cardiac genetic variant interpretation. The engine's notable performance in assessing variants that are classified as variants of unknown significance in ClinVar demonstrates its potential to enhance cardiac genetic testing.

Indexed as

Mutation, MissenseArtificial IntelligenceDatabases, GeneticGenetic Predisposition to DiseaseGenetic TestingGenetic VariationHeart DiseasesHumansMolecular Sequence AnnotationPhenotypeAlphaMissenseartificial intelligencegenetic testinggenotypephenotypeVarCard.Iovariants of unknown significance

Identifiers

PMID39392163
PMCPMC11935564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.